Fortress Biotech Announces Closing of $10.0 Million Public Offering
14 nov. 2023 16h01 HE
|
Fortress Biotech, Inc.
MIAMI, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Announces Pricing of $10.0 Million Public Offering
10 nov. 2023 08h15 HE
|
Fortress Biotech, Inc.
MIAMI, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Announces Launch of Proposed Public Offering
09 nov. 2023 17h05 HE
|
Fortress Biotech, Inc.
MIAMI, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1
16 oct. 2023 09h00 HE
|
Fortress Biotech, Inc.
Recent $11.3 million grant from the California Institute for Regenerative Medicine (CIRM) intended to fund the Phase 1 clinical trial at City of Hope; the Investigational New Drug application for...
Fortress Biotech Announces Reverse Stock Split
09 oct. 2023 12h50 HE
|
Fortress Biotech, Inc.
MIAMI, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and...
Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference
05 oct. 2023 08h30 HE
|
Fortress Biotech, Inc.
Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.
Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
07 sept. 2023 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
14 août 2023 16h01 HE
|
Fortress Biotech, Inc.
Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials...
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023
03 août 2023 08h30 HE
|
Fortress Biotech, Inc.
MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing...
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
29 juin 2023 08h00 HE
|
Fortress Biotech, Inc.
Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese healthy subjects Initiating Phase 1b clinical...